Michael Curtis Overview

  • Investor Type
  • Angel

  • Status
  • Active

  • Professionals
  • 1


  • Investments
  • 1

  • Portfolio
  • 1

Michael Curtis General Information


Mr. Michael Curtis serves as the Chief Development Officer of Ataxion. Dr. Michael Curtis serves as Co-Chief Executive Officer and President at Egenesis. He also served as an Entrepreneur-in-Residence for Atlas Ventures. Prior to joining Ataxion, Dr. Curtis was Senior Vice President of Product Development and Regulatory Affairs at Catabasis Pharmaceuticals with responsibility for all aspects of moving the company's products from research into clinical development. He was previously Vice President of Pharmaceutical Development at Infinity Pharmaceuticals, where he was responsible for manufacturing, formulation, analytical characterization, and drug metabolism/pharmacokinetics. Prior to Infinity, he was with Transkayotic Therapies (currently the Shire), where he was responsible for analytical methods development and validation to support the registration of Elaprase® (idursulfase). Dr. Curtis was previously the Associate Director of Analytical Development at Syntonix Pharmaceuticals (currently Biogen IDEC), where he was involved with advancing the Transceptor™ technology which has resulted in the development of Eloctate™ (rFVIIFc) and Alprolix™ (rFIXFc). Before Syntonix, he was a member of the Therapeutic Protein Research Group at Genzyme, working on the development of the enzyme replacement therapy Myozyme® (alglucosidasealfa). Dr. Curtis began his career at Bristol-Myers Squibb, with positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril), Taxol® (paclitaxel), and the early development of Orencia® (abatacept). Dr. Curtis holds a Ph.D. in cell and molecular biology from Upstate Medical University and a B.S. in biochemistry from the State University of New York College of Environmental Science and Forestry.

Business Details

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Corporate Office
  • Boston, MA
  • United States

Michael Curtis Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Swimply 19-Nov-2021 00000 00000 0000 Information Services (B2C) Generating Revenue 0000000 000000 00.0

Michael Curtis Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Michael Curtis Team (1)

Name Title Deals Funds Boards Office
Michael Curtis Ph.D Angel Investor 0 Boston, MA

Michael Curtis Co-Investors (13)

Name With Exits Lead Partner Series Industry
Dustin Dolginow 1 0 Series chart Industry bar
Mayfield Fund 0 0 Series chart Industry bar
Nathan Blecharczyk 0 0 Series chart Industry bar
Norwest Venture Partners 0 0 Series chart Industry bar
Notable Capital 0 0 Series chart Industry bar

Michael Curtis FAQs

  • Who is Michael Curtis?

    Michael Curtis is an angel Investor who has made 1 investment.

  • What kind of investor is Michael Curtis?

    Michael Curtis is an angel investor.

  • What does Michael Curtis do?

    As an angel investor, Michael Curtis invests personal money into promising companies, typically in exchange for equity.

  • What has Michael Curtis invested in?

    Michael Curtis has invested in Swimply within the Information Services (B2C) industry.

  • What has Michael Curtis invested in recently?

    Michael Curtis's latest investment was on 19-Nov-2021 in Swimply, a company within the Information Services (B2C) industry.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »